World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

PORTAL VEIN THROMBOSIS IN CIRRHOTICS: NOVEL INSIGHTS

Dr Zeeshan Ahmad Wani, *Dr Afaq Ahmad Khan, Dr Sonmoon Mohapatra, Dr Tufeel Kochak,
Rakhi Gupta and Ajeet Singh Bhadoria

ABSTRACT

Among all thrombotic complications, portal vein thrombosis (PVT) is the most common thrombotic condition in cirrhotic patients and is encountered in 10-25% of cirrhotics. Pathophysiologically, cirrhosis is not considered a hypocoagulable state, rather various clinical studies support it as having a thrombotic potential. Risk factors for thrombosis include inherited and acquired deficiency of factors involved in anticoagulation, venous stasis of portal vein and local factors related to endothelium. PVT in cirrhotics may manifest as asymptomatic condition to life threatening complications e.g variceal bleed and gut infarction. Anticoagulation therapy forms important strategy in patients of cirrhosis with PVT, although robust guidelines dictating such issues are lacking. LMW Heparin and vitamin K antagonists are being successfully used to treat PVT in cirrhosis but still a proper drug regimen and monitoring is incompletely explored area. Use of direct thrombin inhibitors and Xa inhibitors has its own limitation in liver disease patients. New group of patients like Non Alcoholic fatty liver disease (NAFLD) related cirrhosis have high risk of PVT. Further what is the risk of PVT in non cirrhotic NAFLD patients is yet not fully studied especially in patients with metabolic syndrome and insulin resistance. Is it a true fact that a third front of adult idiopathic PVT is based on endothelial dysfunction related to metabolic syndrome contrasting western occult MPD as etiology v/s childhood Asian infectious and immune etiology of PVT/EHPVO. Thrombectomy and TIPS may be considered as second line options after anticoagulation. Further appealed MELD scores are still not an option for advanced PVT in cirrhotic patients while considering them for liver transplant. In this review we address useful information regarding the new insights in terms of etiopathogenesis, mechanisms and management of PVT in cirrhotic patients.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR